StockRunway.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
New York, NY -- (SBWIRE) -- 01/27/2014 -- StockRunway.com issues special report on: PDC Energy Inc (NASDAQ:PDCE), Quiksilver, Inc.(NYSE:ZQK), Pacific Biosciences of California (NASDAQ:PACB), Immunomedics, Inc.(NASDAQ:IMMU)
PDC Energy Inc (NASDAQ:PDCE) opened its shares at the price of $49.16 for the day. Its closing price was $46.97 after losing -5.28% for the day. The company traded with the total volume of 1.22 million shares, while its average trading volume remained 950,642.00 shares. The beta of PDCE stands at1.85. PDC Energy, Inc., an independent energy company, acquires, explores, develops, and produces crude oil, natural gas, and natural gas liquids (NGLs) in the United States.
Has PDCE Found The Bottom and Ready To Move Up? Find Out Here
Quiksilver, Inc.(NYSE:ZQK) percentage change plunged -5.06% to close at $7.13 with the total traded volume of 2.06 million shares, and average volume of 1.56 million. The 52 week range of the stock remained $4.81 - $9.29, while its day lowest price was $7.12 and it hit its day highest price at $7.45. Quiksilver, Inc. designs, develops, markets, and distributes branded apparel, footwear, accessories, and related products primarily for men, women, and children. The company provides its products for various activities, including casual and outdoor lifestyle associated with surfing.
Has ZQK Found The Bottom And Ready To Gain Momentum? Find Out Here
Pacific Biosciences of California (NASDAQ:PACB) started its trading session with the price of $7.27 and closed at $6.99 by scoring -4.90%. PACB’s stocks traded with total volume of 1.14 million shares, while the average trading volume remained 997,886.00 shares. The beta of PACB stands at 3.14. Day range of the stock was $6.65 -$7.42. Pacific Biosciences of California, Inc. develops, manufactures, and markets an integrated platform for genetic analysis. The company engages in developing a single molecule, real-time, (SMRT) technology for the detection of biological processes.
Why Should Investors Buy PACB After the Recent Fall? Just Go Here and Find Out
Immunomedics, Inc.(NASDAQ:IMMU) ended its day with the loss of -4.89% and closed at the price of $5.25 after opening at $5.45. Stock traded during its last trading session with the total volume of 1.26 million shares, as compared to its average volume of 1.30 million shares. Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus.
Will IMMU Get Buyers Even After The Recent Rally? Find Out Here
StockRunway.com is an Elite Financial Stock website catering to individual investors, fund managers, investment bankers and equity analysts. Whether you're new to penny stocks or a seasoned veteran, you'll find all the information you will need right here! Our research is a remarkable educational tool for everyone to utilize.
Sign up TODAY and join the vast amount of investors already benefiting from the best free alerts from StockRunway's service today!
This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site, Press Releases or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockRunway.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Read our Full Disclaimer by visiting our website.
Read Our Full Disclaimer at: http://www.stockrunway.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)